English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA transformative gift to expand research and breakthrough therapies, an upcoming conference on managing neuroendocrine tumors, FDA approval of Imetelstat for patients with anemia from myelodysplastic syndromes and a researcher advocating for making bereavement care a public health priority are all included in this month’s tip sheet from Sylvester Comprehensive Cancer Center.
Tag: Neuroendocrine Tumors
Merkel cell carcinoma expert for interviews. Dr. Aman Chauhan leads the Neuroendocrine Tumor Program @SylvesterCancer.
If you are seeking an expert to discuss diagnosis, treatment and the latest research related to Merkel cell carcinoma, also known as neuroendocrine carcinoma of the skin, Aman Chauhan, M.D., is available. Dr. Chauhan leads the Neuroendocrine Tumor Program at…
Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors
New research in JNCCN finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. Only 51.7% of patients perceived that they had the same treatment goals as their physician.
Cleveland Clinic Names Michelle Kang Kim, M.D., Ph.D., Chair of the Department of Gastroenterology, Hepatology and Nutrition
Cleveland Clinic has appointed Michelle Kang Kim, M.D., Ph.D., as chair of the Department of Gastroenterology, Hepatology and Nutrition with Cleveland Clinic’s Digestive Disease & Surgery Institute. Dr. Kim’s will start Aug. 1. She will succeed Miguel Regueiro, M.D., who has served as interim chair of the department since May 2021, following his appointment as chair of Cleveland Clinic’s Digestive Disease & Surgery Institute.
UK HealthCare Launches Pediatric Neuroendocrine Tumor Program
UK HealthCare recently launched a new Pediatric Neuroendocrine Tumor Clinical and Research Program to improve treatment for children diagnosed with or at high risk for developing rare neuroendocrine tumors (NETs). This program is a joint effort between the University of Kentucky Markey Cancer Center and the Kentucky Children’s Hospital and is one of only a handful of centers specializing in this field in the world.
JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions
New study in JNCCN finds that among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varies by primary tumor site, in first population-based cohort study on cancer-specific death after a NET diagnosis.